Last updated: March 27, 2026
What Is NDC 33342-0043?
NDC 33342-0043 refers to a specific drug product. Based on available databases, this code corresponds to Rituximab, a monoclonal antibody used primarily for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
Market Size and Sales Data
Current Market Estimates (2022–2023)
| Metric |
Details |
| Global Market Size |
Estimated at USD 8.3 billion in 2022 |
| Key Markets |
United States (50%), European Union (20%), Asia-Pacific (15%) |
| Growth Rate |
Compound annual growth rate (CAGR) of approximately 4% through 2027 |
| Market Share of Rituximab |
Dominates 65% of anti-CD20 monoclonal antibody market |
Sales Trends
- US sales for Rituximab reached USD 4.1 billion in 2022.
- Sales doubled between 2015 and 2022, driven by expanding indications and biosimilar entries.
- Biosimilar competition in the US began in 2019 with Pfizer’s Truxima, resulting in a 15% price reduction for branded Rituximab, with further downward pressure projected.
Key Competitors
- Ruxience (Samsung Bioepis/Celltrion)
- Truxima (Pfizer)
- Yblesa (Celltrion)
- Biosimilar presence reduces pricing power of originator.
Pricing Dynamics and Forecasts
Current Pricing
| Region |
Average Wholesale Price (AWP) per vial |
Notes |
| US |
USD 2,500 – USD 3,200 per 500 mg vial |
Brand name (MabThera) averages USD 2,750 |
| Europe |
EUR 2,200 – EUR 2,900 per vial |
Slightly lower than US, varies by country |
| Asia-Pacific |
USD 1,800 – USD 2,500 per vial |
Prices are generally lower due to market competition |
Price Reduction Trends
- Biosimilar entry in 2019 reduced prices by 15–30%.
- Anticipate continuous downward pressure, with pricing expected to decline an additional 10–15% over the next 3 years.
- US Medicare reimbursement rates tend to set the benchmark for biosimilar and branded pricing.
Projections (2024–2028)
| Year |
Estimated Price Range per 500 mg vial |
Rationale |
| 2024 |
USD 2,100 – USD 2,600 |
Continued biosimilar penetration; mild pricing pressure |
| 2025 |
USD 2,000 – USD 2,450 |
Increased biosimilar adoption; competitive market dynamics |
| 2026 |
USD 1,900 – USD 2,300 |
Further biosimilar market expansion; potential for negotiated discounts |
| 2027 |
USD 1,850 – USD 2,200 |
Market stabilization with ongoing biosimilar competition |
| 2028 |
USD 1,800 – USD 2,150 |
Market maturity; price stabilization, potential for new biosimilar entries |
Regulatory and Policy Impact
- The FDA approved biosimilars Truxima (2019) and Ruxience (2019), both of which faced initial market resistance.
- CMS and private payers increasingly favor biosimilars due to cost savings.
- Biologics price competition regulations and patent expirations influence market share and pricing.
Future Market Drivers
- Expansion into new indications such as multiple sclerosis.
- Development of next-generation biosimilars with improved efficacy or administration convenience.
- Increasing adoption of biosimilars by healthcare systems to reduce costs.
- Patent litigation and exclusivity periods influence availability of biosimilars.
Key Takeaways
- Rituximab (NDC 33342-0043) remains a dominant biologic therapy, with USD 8.3 billion global sales in 2022.
- Biosimilar competition has reduced average prices by 15–30% since 2019.
- Price projections indicate a gradual decline of approximately 10–15% over the next five years.
- Regulatory policies and market dynamics favor biosimilar adoption, further pressuring prices.
- The US market remains the largest and most influential, with ongoing negotiations impacting future pricing.
FAQs
1. How will biosimilar competition affect Rituximab prices?
Biosimilars have already caused a significant price reduction and will continue to do so, with prices expected to decline another 10–15% through 2028.
2. What factors influence Rituximab’s market growth?
Expansion of approved indications, biosimilar entry, regulatory policies, and healthcare system adoption drive market growth.
3. Are there upcoming regulatory approvals that could impact prices?
Yes, new biosimilars and next-generation formulations are in development stages, potentially increasing market competition.
4. Which regions have the highest sales for Rituximab?
The US accounts for roughly 50% of global sales, followed by the European Union.
5. How do healthcare policies influence Rituximab’s pricing?
Policies promoting biosimilar use and negotiated reimbursement rates contribute to downward pricing pressure.
References
[1] IQVIA. (2023). Global Oncology Market Review.
[2] FDA. (2019). Biologics Price Competition and Innovation Act.
[3] EvaluatePharma. (2023). Pharmaceutical Market Outlook.
[4] Centers for Medicare & Medicaid Services. (2022). Biosimilar reimbursement policies.
